TD Cowen reiterates Buy rating on Agios Pharma stock amid safety concerns

Agios Pharmaceuticals (AGIO) is managing recent safety concerns regarding its drug mitapivat (PYRUKYND) following FDA adverse event reports, which analysts like TD Cowen contend are not directly linked to the medication. Despite reporting a larger-than-expected Q2 2025 loss per share, the company significantly surpassed revenue expectations with $12.5 million and maintains a strong cash position. TD Cowen reiterated AGIO as a "top pick," citing anticipated broad U.S. thalassemia approval and future success in sickle cell disease with Phase 3 data expected in late 2025, a sentiment reinforced by recent Saudi Arabian approval and BofA Securities raising its price target to $52.

Analysis

Agios Pharmaceuticals (AGIO) is currently navigating significant investor focus on the safety profile of its key drug, mitapivat, following FDA Adverse Event Reporting System (FAERS) reports of patient deaths. Despite this headline risk, which has caused share price volatility, prominent analysts like TD Cowen and BofA Securities maintain a bullish outlook. TD Cowen asserts that the reported cases do not establish a causal link to the medication and has reiterated AGIO as its "top pick," a sentiment supported by BofA Securities raising its price target to $52 from $50. Financially, the company's Q2 2025 results present a mixed but ultimately positive picture for growth; while the loss per share of -$1.93 was wider than the -$1.81 forecast, revenues of $12.5 million significantly surpassed the $9.54 million consensus. This revenue beat, coupled with a strong balance sheet reported to have more cash than debt, provides a financial cushion. The investment thesis is heavily weighted towards future catalysts, including the anticipated broad U.S. label for mitapivat in thalassemia, recent approval in Saudi Arabia which acts as a positive commercial precedent, and pivotal Phase 3 data for sickle cell disease expected in late 2025.

Key Decisions for Investors

• Investors with a higher risk tolerance may consider the recent stock volatility driven by safety concerns as a potential entry point, given the strong analyst support and a long-term thesis based on future clinical and commercial milestones.
• Monitor all communications from the company and the FDA regarding the mitapivat (PYRUKYND) safety profile, as this is the primary overhang and any definitive negative findings could severely impact the stock's valuation.
• Focus on the company's ability to maintain revenue momentum beyond the Q2 beat and watch for any updates or delays related to the pivotal Phase 3 sickle cell data readout expected in late 2025, which is a key catalyst for the stock.